Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Improving the use of MRD for the prognosis and treatment of ALL

Rashmi Kanagal-Shamanna • 28 Sep 2022
SOHO 2022
Acute Lymphoblastic Leukemia Leukemia

Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly explains the importance of measurable residual disease (MRD) in the prognosis and treatment of patients with acute lymphoblastic leukemia (ALL), and comments on ways to improve and standardize the use of MRD in this disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rashmi Kanagal-Shamanna

1:17
Common germline mutations in myelodysplastic syndromes
Rashmi Kanagal-Shamanna • 7 Jun 2023
1:23
Looking forward to the Cancer Genomics Consortium Annual Meeting
Rashmi Kanagal-Shamanna • 7 Jun 2023
4:06
Incidence of germline mutations in patients with myeloid neoplasms with antecedent solid tumors
Rashmi Kanagal-Shamanna • 7 Jun 2023
1:29
Automated tool for MDS classification using the WHO & ICC classification systems
Rashmi Kanagal-Shamanna • 5 May 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals